47 results
Page 2 of 3
6-K
EX-99.2
idpp 31hdackk
14 Nov 22
Condensed Interim Consolidated Financial Statements
1:04pm
424B4
5goxg1 9raz
5 Oct 22
Prospectus supplement with pricing info
5:24pm
POS AM
p0x5jg8lydlh5giwa
29 Sep 22
Prospectus update (post-effective amendment)
9:49pm
F-1/A
3qkstyhi eqfj
21 Sep 22
Registration statement (foreign) (amended)
4:20pm
F-1
tlne6
8 Sep 22
Registration statement (foreign)
1:02pm
6-K
EX-99.1
dh2isamzfn0
22 Aug 22
XORTX Announces Positive Topline Results from Part 2 Pharmacokinetics Bridging Study
7:46am
DRS
js2kpnjm
15 Aug 22
Draft registration statement
12:00am
6-K
EX-99.2
0hfg5klps liwrdbxkqv
11 Aug 22
Condensed Interim Consolidated Financial Statements
7:00am
6-K
EX-99.1
fcejy
14 Jul 22
XORTX Announces Positive Topline Results from Pharmacokinetics Bridging Clinical Trial
11:03am
6-K
EX-99.1
j1c9x
29 Jun 22
Current report (foreign)
9:58pm
6-K
EX-99.2
pe9o6c
16 May 22
Condensed Interim Consolidated Financial Statements
7:25am
20-F
x3jk 4z8cb
3 May 22
Annual report (foreign)
5:29pm
20-F
EX-4.22
26mb5l4m
3 May 22
Annual report (foreign)
5:29pm
20-F
EX-15.1
712f2mk6fz4
3 May 22
Annual report (foreign)
5:29pm
20-F
EX-11.1
2jnlve8 uw
3 May 22
Annual report (foreign)
5:29pm
20-F
EX-4.20
trpp4 sk5i1d
3 May 22
Annual report (foreign)
5:29pm
6-K
EX-99.1
5q4ymhysbjcjgubz hb
3 May 22
XORTX Initiates Dosing of Human Subjects in the XRX-OXY-101 Clinical Trial
7:03am
6-K
EX-99.1
aqigmrnc
13 Apr 22
Current report (foreign)
7:23am
6-K
EX-99.2
qaxgm2
13 Apr 22
Consolidated Financial Statements
7:22am
6-K
EX-99.2
5nf6q3ax
29 Nov 21
Condensed Interim Consolidated Financial Statements
12:00am